FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of anticancer therapy, namely to a combination of a sulphonamide compound and an immune regulator, a method of treating and/or preventing a tumour using such a combination and to the use of such a combination. Disclosed is a combination of a PD-1 pathway antagonist and a sulphonamide compound which is 5-chloro-2-(N-((1S,2R)-2-(6-fluoro-2,3-dimethylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)sulfamoyl)benzamide, or a salt thereof, for treating and/or preventing a tumour, as well as using said sulfonamide compound in combination with a PD-1 pathway antagonist for treating and/or preventing a tumour and for preparing a drug for treating and/or preventing a tumour. Disclosed method of treating and/or preventing a tumour involves administering to a patient an effective amount of said sulphonamide compound in a combination with a PD-1 pathway antagonist.
EFFECT: use of the group of inventions provides intensified anticancer action when using said sulphonamide compound in combination with a PD-1 pathway antagonist.
20 cl, 4 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOR AGENT | 2018 |
|
RU2770824C2 |
| SULPHONAMIDE COMPOUND OR SALT THEREOF | 2017 |
|
RU2732572C2 |
| NEW CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | 2017 |
|
RU2770727C2 |
| CANCER CHEMOTHERAPY USING AZABICYCLO COMPOUND | 2018 |
|
RU2821034C2 |
| ANTITUMOR AGENT AND ANTITUMOR EFFECT AMPLIFIER | 2018 |
|
RU2783759C2 |
| ANTITUMOR EFFECT STRENGTHENING AGENT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | 2018 |
|
RU2799006C2 |
| INHIBITORS OF FACTOR VIIA | 2000 |
|
RU2248359C2 |
| 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 2020 |
|
RU2796605C2 |
| NOVEL PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND OR SALT THEREOF | 2016 |
|
RU2705579C2 |
| AZAINDOLE DERIVATIVE | 2015 |
|
RU2649575C1 |
